Webinar archive
Deciphering Disease Webinars
A curated archive of 13 hour-long research webinarsfeaturing leading scientists discussing recent progress toward therapies in cancer, aging, neurodegeneration, fibrosis, and the proteomics-driven drug discovery pipeline. Each talk is organised below by theme alongside the relevant courses on this site.
Cancer Immunotherapy
The mechanistic basis of CAR-T, innate-immune oncology, and the cellular dialogue between tumour and immune system. Maps onto the immune-evasion hallmark and the modern therapy module.
Deciphering CAR-T Cells: Functional Mechanisms for Next-Generation Immunotherapy
Engineering chimeric-antigen-receptor T cells, the molecular logic of activation domains (CD28 vs 4-1BB), persistence, exhaustion, and the next wave of CAR designs to extend CAR-T to solid tumours.
Deciphering Immuno-oncology: Targeting Innate Immunity in Cancer
Beyond T cells — NK cells, macrophages, the cGAS-STING axis, TLR agonists, and how innate-immune activation can amplify or replace checkpoint-blockade benefit.
Deciphering Immuno-Oncology: Cellular Mechanisms of the Tumor Immune Response
The cell-by-cell anatomy of the tumour-immune dialogue: dendritic-cell antigen presentation, T-cell priming in lymph nodes, exhaustion phenotypes, and TME-imposed dysfunction.
Cancer Biology — Genomics, Epigenetics, Metabolism
Three talks on the integrating mechanisms of tumour biology: genomic instability as the enabler, epigenetic immune-axis regulation, and the metabolite-cofactor link to chromatin biology.
Deciphering Epigenetic Regulation of the Immune Response in Cancer
Histone modifications, DNA methylation and chromatin states governing T-cell exhaustion and tumour antigen presentation; therapeutic implications of HDAC and EZH2 inhibitors.
Deciphering Cancer: Genomic Instability in Cancer
Mutator phenotypes, replication stress, chromothripsis, and the actionable consequences for synthetic-lethality strategies (PARP, ATR, WEE1 inhibitors).
Deciphering Cancer: The Intersection of Epigenetics, Metabolism, and Tumorigenesis
How metabolite pools (α-KG, 2-HG, SAM, acetyl-CoA) act as cofactors for chromatin-modifying enzymes — IDH-mutant gliomas, SDH/FH-deficient tumours, and the metabolic-epigenetic axis.
Oncology Drug Discovery — Degraders & Proteomics
Targeted protein degradation (PROTACs, molecular glues) and quantitative proteomics as the modern engines of drug-discovery; methodology talk on PTM enrichment for LC-MS.
Targeted Protein Degradation to Advance Oncology Drug Discovery
PROTACs and molecular glues — heterobifunctional and homotrimeric degraders, ternary-complex chemistry, MoA selectivity, and the clinical pipeline beyond ARV-110 and KT-474.
Targeting Proteomics to Decipher Biology for the Drug Development Pipeline
Mass-spec-based proteomics from target identification through clinical biomarker development — quantitative workflows, post-translational-modification analysis, and patient stratification.
Highly Sensitive, Post-translationally Modified Peptide Enrichment for LC-MS Analysis
Methodology talk — IMAC, TiO₂, antibody-based enrichment of phospho-, acetyl-, and ubiquitin-modified peptides for high-coverage PTM mapping at the proteome scale.
Aging & Neurodegeneration
Senescence as cancer-aging axis, the inflammation arm of Alzheimer's pathogenesis, and the central role of RNA-binding proteins in neurodevelopmental and degenerative disease.
Deciphering Aging: Linking Senescence with DNA Damage and the Cell Cycle
The senescence-associated secretory phenotype (SASP), p16/p21 cell-cycle arrest, persistent DNA-damage signalling, and senolytics (dasatinib + quercetin, fisetin, navitoclax).
Deciphering Neurodegeneration: Inflammation, Immune Response, and Alzheimer's
Microglial activation, TREM2 biology, complement pathway in synapse pruning, the neuroinflammation arm of AD pathogenesis, and emerging anti-inflammatory therapeutic approaches.
Deciphering the Role of RNA-Binding Proteins in Neurodevelopment and Disease
RBPs as master regulators of neuronal mRNA fate — splicing, transport, local translation; pathologies including FXS, ALS (TDP-43, FUS), and SMA.
Fibrosis
Convergent mechanisms of fibrotic disease across the liver and heart — myofibroblast biology, TGF-β-driven fibrosis, and current anti-fibrotic strategies.
Deciphering Fibrosis: Drivers of Fibrotic Disease in the Liver and Heart
Hepatic stellate cells, cardiac fibroblasts, TGF-β-driven myofibroblast activation, and the converging mechanisms of organ fibrosis with therapeutic targeting (anti-fibrotic agents).
Cross-references in the course library
Cancer Part VI — Tumour Microenvironment
Pairs with the immuno-oncology and TME-evasion talks above.
Cancer Part VIII — Therapy
Pairs with the CAR-T and protein-degrader talks; covers checkpoint blockade and CAR-T in clinical context.
Cancer Part IV — Genome Instability
Pairs with the “Genomic Instability in Cancer” talk; covers PARP and synthetic lethality.
Cancer Part V — Cancer Metabolism
Pairs with “Epigenetics, Metabolism, and Tumorigenesis” (oncometabolites, IDH).
Alzheimer Part IV — Tau & Tauopathy
The neurodegeneration-inflammation talk above complements the TREM2 and microglial-biology section here.
Alzheimer Part VIII — Future Directions
The senescence/SASP talk maps onto senolytic-strategy discussion in this module.